Ticker > Company >

Venus Remedies share price

Venus Remedies Ltd.

NSE: VENUSREM BSE: 526953 SECTOR: Pharmaceuticals & Drugs  32k   68   5

315.25
-3.25 (-1.02%)
BSE: 08 Nov 04:01 PM

Price Summary

Today's High

₹ 329.05

Today's Low

₹ 315.25

52 Week High

₹ 429.6

52 Week Low

₹ 280

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

421.39 Cr.

Enterprise Value

392.43 Cr.

No. of Shares

1.34 Cr.

P/E

12.25

P/B

0.8

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  392.45

CASH

67.64 Cr.

DEBT

38.68 Cr.

Promoter Holding

41.76 %

EPS (TTM)

₹  25.74

Sales Growth

6.98%

ROE

6.18 %

ROCE

8.77%

Profit Growth

5.3 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.98%
3 Year3.78%
5 Year13.77%

Profit Growth

1 Year5.3%
3 Year-17.48%
5 Year25.59%

ROE%

1 Year6.18%
3 Year8.05%
5 Year7.36%

ROCE %

1 Year8.77%
3 Year8.78%
5 Year7.66%

Debt/Equity

0.0761

Price to Cash Flow

11.91

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

2.03577676963098

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 41.76 0.00
Jun 2024 41.76 0.00
Mar 2024 41.76 0.00
Dec 2023 41.76 0.00
Sep 2023 41.76 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 81.5068 days.
  • Company has a healthy liquidity position with current ratio of 4.9578.
  • The company has a good cash flow management; CFO/PAT stands at 2.03577676963098.

 Limitations

  • The company has shown a poor profit growth of -17.4769059588115% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.77980604344901% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 170.19 131.23 175.16 105.86 167.02
Total Expenditure 157.06 118.23 153.88 91.58 156.75
Operating Profit 13.13 13 21.28 14.28 10.27
Other Income 2.93 2.42 3.91 1.56 10.71
Interest 0 0 0 0 0
Depreciation 6.21 6.3 5.72 5.76 6.17
Exceptional Items 0 0 0 0 0
Profit Before Tax 9.85 9.12 19.47 10.08 14.81
Tax 4.4 0.93 6.96 5.63 5.55
Profit After Tax 5.45 8.19 12.51 4.45 9.26
Adjusted EPS (Rs) 4.08 6.13 9.36 3.33 6.93

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 320.23 514.62 576.71 537.66 575.21
Total Expenditure 277.16 467.76 507.89 476.14 514.32
Operating Profit 43.07 46.86 68.82 61.53 60.89
Other Income 3.58 17.76 8.43 10.17 11.32
Interest 13.05 12.73 0 0 0
Depreciation 31.05 34.28 32.58 31.37 25.55
Exceptional Items -8.81 23.44 0 0 0
Profit Before Tax -6.26 41.06 44.67 40.33 46.65
Tax 1.96 -13.21 -4.32 11.36 16.15
Net Profit -8.23 54.27 48.99 28.96 30.5
Adjusted EPS (Rs.) -6.67 43.97 36.65 21.67 22.82

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 12.34 12.34 13.37 13.37 13.37
Total Reserves 319.91 387.84 436.05 464.68 495.22
Borrowings 72.26 47.52 38.68 38.68 38.68
Other N/C liabilities 23.77 11.29 7.27 19.49 21.18
Current liabilities 215.98 87.82 82.61 72.67 72.81
Total Liabilities 644.27 546.81 577.98 608.89 641.26
Assets
Net Block 271.47 244.2 224.67 199.68 202.76
Capital WIP 24.63 25.11 25.23 26.1 21.08
Intangible WIP 0 0 0 0 0
Investments 0.14 0.14 0.14 0.14 0.16
Loans & Advances 64.08 62.34 61.96 62.55 51.76
Other N/C Assets 0 1.29 1.57 2.23 4.5
Current Assets 283.94 213.74 264.41 318.19 361
Total Assets 644.27 546.81 577.98 608.89 641.26
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 2.55 17.62 44.67 40.33 46.65
Adjustment 40.39 21.59 24.83 22.25 19.36
Changes in Assets & Liabilities 20.37 69.69 -28.5 -34.53 -15.15
Tax Paid 0 0 0 0 -15.48
Operating Cash Flow 77.75 132.34 41 28.05 35.38
Investing Cash Flow -4.64 55.98 -16.75 -50.81 -6.94
Financing Cash Flow -72.35 -161.88 -9.13 0 0
Net Cash Flow 0.76 26.45 15.12 -22.76 28.44

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 41.76 41.76 41.76 41.76 41.76
manu chaudhary 11.73 11.73 11.73 11.73 11.73
pawan chaudhary - - 12.82 12.82 12.82
sunev pharma solutions li... 17.21 17.21 17.21 17.21 17.21
pawan chaudhary 12.82 12.82 - - -
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 58.24 58.24 58.24 58.24 58.24
acadian emerging markets ... - - 1.05 1.05 1.10
investor education and pr... - 1.00 1.00 - 1.00
k.b.shekar - 1.92 1.97 1.97 1.97
llp - 0.27 0.17 0.39 0.12
mc jain infoservices priv... - - 1.28 1.50 2.32
pradeep kumar jain 1.21 - 1.19 1.87 2.00
investor education and pr... 1.00 - - 1.00 -
k.b. shekhar 1.93 - - - -

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Venus Remedies informs about press release 5 Nov, 11:37 AM Venus Remedies secures Malaysian PIC/S GMP approval for pre-filled syringe facility 5 Nov, 10:44 AM Venus Remedies - Quaterly Results 29 Oct, 9:59 PM Venus Remedies - Quaterly Results 29 Oct, 9:59 PM Venus Remedies informs about closure of trading window 24 Sep, 5:27 PM Venus Remedies - Quaterly Results 13 Aug, 7:28 PM Venus Remedies informs about postponement of board meeting 17 Jul, 10:16 AM Venus Remedies informs about closure of trading window 26 Jun, 10:05 AM Venus Remedies gets oncology tender from PAHO 19 Jun, 10:50 AM Venus Remedies informs about updates 13 Jun, 12:21 PM Venus Remedies secures award for antibiotic product Ceftriaxone 1gm from UNICEF 13 Jun, 9:50 AM Venus Remedies informs about newspaper publication 1 Jun, 3:03 PM Venus Remedies - Quaterly Results 30 May, 8:54 PM Venus Remedies informs about disclosure 1 Apr, 12:58 PM Venus Remedies gets marketing authorisations from Ukraine for three cancer drugs 18 Mar, 4:47 PM Venus Remedies obtains Marketing Authorizations for range of essential oncology drugs in Ukraine 9 Mar, 3:39 PM Venus Remedies awarded first incentive of Rs 7.50 crore under PLI scheme 6 Mar, 10:30 AM Venus Remedies informs about press release 6 Mar, 9:33 AM Venus Remedies - Quaterly Results 14 Feb, 8:01 PM Venus Remedies - Quaterly Results 14 Feb, 8:01 PM Venus Remedies secures marketing authorizations for Docetaxel, Gemcitabine in Europe 12 Jan, 12:30 PM Venus Remedies secures marketing authorizations for Docetaxel in Israel, Cytarabine in Colombia 21 Dec, 3:13 PM Venus Remedies’ R3SET forays into wellness arena 20 Dec, 2:10 PM Venus Remedies informs about press release 20 Dec, 12:56 PM Venus Remedies informs about disclosure 5 Dec, 12:16 PM Venus Remedies gets market authorizations for Enoxaparin in Azerbaijan 5 Dec, 11:09 AM Venus Remedies informs about press release 1 Dec, 2:06 PM Venus Remedies informs about unaudited financial results 25 Nov, 3:19 PM Venus Remedies informs about press release 6 Nov, 10:23 AM Venus Remedies secures ‘Three Star Export House’ certificate from Government of India 6 Nov, 9:49 AM Venus Remedies informs about press release 1 Nov, 10:45 AM Venus Remedies wins FICCI Healthcare Award 2023 1 Nov, 9:52 AM Venus Remedies achieves market authorization for Bleomycin in United Kingdom 26 Oct, 12:07 PM Venus Remedies informs about press release 26 Oct, 10:38 AM Venus Remedies informs about press release 20 Oct, 11:24 AM Venus Remedies informs about press release 16 Oct, 10:25 AM Venus Remedies gets marketing approval for six chemotherapy drugs from Philippines 16 Oct, 9:49 AM Venus Remedies expands global reach with launch of Elores in Ecuador 12 Oct, 3:39 PM Venus Remedies informs about details of loss of certificate 26 Sep, 4:49 PM Venus Remedies informs about loss of share certificate 23 Sep, 4:31 PM Venus Remedies secures marketing authorization from Serbia for gemcitabine and docetaxel 20 Sep, 11:29 AM Venus Remedies informs about press release 20 Sep, 11:19 AM Venus Remedies registers with DSIR to avail custom duty exemption 14 Sep, 2:10 PM Venus Remedies gets marketing approval from Saudi Arabia for Enoxaparin in pre-filled syringes 28 Aug, 2:09 PM Venus Remedies launches R&D drug Elores in Oman 17 Aug, 12:41 PM Venus Remedies - Quaterly Results 14 Aug, 7:29 PM Venus Remedies informs about press release 31 Jul, 12:21 PM Venus Remedies gets marketing approvals for oncology products across 76 countries 31 Jul, 11:53 AM Venus Remedies informs about update on trading restriction of company shares 24 Jul, 5:06 PM Venus Remedies informs about press release 24 Jul, 12:13 PM

Venus Remedies Stock Price Analysis and Quick Research Report. Is Venus Remedies an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Venus Remedies and its performance over the period of time. Venus Remedies stock price today is Rs 317.25.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Venus Remedies cash from the operating activity was Rs 35.3826 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Venus Remedies has a Debt to Equity ratio of 0.0761 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Venus Remedies , the EPS growth was 5.3031 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Venus Remedies has OPM of 10.5858809719679 % which is a bad sign for profitability.
     
  • ROE: Venus Remedies have a poor ROE of 6.1827 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Venus Remedies is Rs 317.25. One can use valuation calculators of ticker to know if Venus Remedies share price is undervalued or overvalued.
Last Updated on:
Brief about Venus Remedies
X